Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34 + Selection Systems
Open Access
- 1 July 1997
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 15 (4) , 297-304
- https://doi.org/10.1002/stem.150297
Abstract
Autologous peripheral blood progenitor cell (PBPC) transplantation is increasingly being used for treatment of indolent lymphomas. Since involvement of bone marrow and peripheral blood is frequent and methods to reduce the lymphoma cell load of PBPC grafts are thus highly desirable, we have studied purging of PBPC comparing two immunomagnetic CD34+ selection systems (VarioMACS™, Miltenyi Biotech; Bergisch Gladbach, Germany, and Isolex50™ System, Baxter; Irvine, CA). Samples of freshly collected mobilized PBPCs were contaminated with BALM‐3 or KARPAS422 lymphoma cells that had been labeled with the fluorescent DNA stain Hoechst 33342. The mixture was subjected to separation with the two devices and the resulting “CD34+” fractions were screened for lymphoma cells by limiting dilution using fluorescence microscopy and by polymerase chain reaction amplification of t(14;18) or CDRIII‐rearrangements. Both devices yielded comparable purities (MACS 97% [87%‐99%]; Isolex 97% [84%‐99%]) and recoveries of CD34+ cells (MACS 56% [30%‐81%]; Isolex 45% [24%‐63%]). The overall depletion of lymphoma cells was 3.9 log (2.6‐5.9), however, residual contaminating cells were seen in every single experiment. The purging efficacy was dependent on the type of contaminating lymphoma cell (BALM‐3: 4.4 log [3.7‐4.8]; KARPAS422: 3.2 log [2.6‐4.2]; p = 0.018), whereas the type of selection system used or the percentage of CD34+ cells in the starting material had no influence. We conclude that excellent purification of CD34+ cells leading to a vigorous depletion of lymphoma cells can be achieved with both CD34+ selection systems investigated. However, the efficacy of purging may greatly differ between individual lymphomas, and complete eradication of contaminating cells from PBPC grafts may rarely be achieved with CD34+ selection alone.Keywords
This publication has 30 references indexed in Scilit:
- Large-Scale Isolation of CD34+ Cells Using the Amgen Cell Selection Device Results in High Levels of Purity and RecoveryJournal of Hematotherapy, 1997
- The ISHAGE Guidelines for CD34+ Cell Determination by Flow CytometryJournal of Hematotherapy, 1996
- Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patientsThe Lancet, 1996
- Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1994
- Gene Marking to Improve the Outcome of Autologous Bone Marrow TransplantationJournal of Hematotherapy, 1994
- Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.Journal of Clinical Oncology, 1994
- Positive Selection of CD34+Cells: A Short Review of the Immunoadsorption Methods Currently Available for Experimental and Clinical UseJournal of Hematotherapy, 1993
- Detection and clinical significance of minimal tumor cell contamination of peripheral stem call harvestsThe International Journal of Cell Cloning, 1992
- Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell LymphomaNew England Journal of Medicine, 1991
- Prolonged Disease-Free Survival after Autologous Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma with a Poor PrognosisNew England Journal of Medicine, 1987